Satisfactory clinical and radiologic outcomes with a new shorter and modular stem for end-stage hip osteoarthritis: an international prospective multicentre pilot study

Riccardo D’Ambrosi1,*, Aldo Toni2, Jaroslaw Czubak3, Jorge Guadilla4, Lawrence Lieber5, Ilaria Mariani6, and Nicola Ursino1

1 IRCCS Istituto Ortopedico Galeazzi, 20161 Milano, Italy
2 IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy
3 SPSK im.Prof.A.Grucy, 05-400 Otwock, Poland
4 HUA Santiago, 01004 Vitoria, Spain
5 DuPage Medical Group Ltd., Downers Grove, IL 60540, USA
6 Institute for Maternal and Child Health – IRCCS “Burlo Garofolo”, 34137 Trieste, Italy

Abstract – Introduction: This multicenter prospective cohort study aimed to assess the safety and clinical and radiologic performance of the CLS® Brevius™ Stem with Kinectiv® Technology. Material and Methods: A total of 222 consecutive subjects, recruited in five different centers, qualifying for primary total hip arthroplasty (THA), were enrolled in the study. All the subjects received the CLS® Brevius™ Stem with Kinectiv® Technology. All the enrolled study subjects underwent pre-operative clinical and radiographic evaluation. Additionally, all subjects underwent post-operative clinical, functional and radiographic evaluations at 6 months and 1, 2, 3, and 5 years. These evaluations included implant survival, pain and functional performance (Harris Hip Score [HHS], University of California, Los Angeles [UCLA] Activity Score, Oxford Hip Score), subject quality-of-life (EQ-5D), radiographic parameters, complications, and concentration of metal ions (aluminum and titanium) in blood. Results: No revisions were performed during the follow-up period. Of the 222 patients, only 76 completed the 5-year follow-up. Only 7 and 5 patients had aluminum and titanium 5-year evaluations, respectively. All the clinical parameters showed an overall improvement in the overtime measured with ANOVA for repeated measures; furthermore, the clinical scores showed a statistically significant improvement at 5 years with respect to pre-operative value (p < 0.001). Aluminum and titanium showed no variation for repeated measures at different time points (p > 0.05). A total of six complications were reported, of which only two were hip-related. Conclusions: The function of the CLS® Brevius™ Stem with Kinectiv® Technology indicated that subject well-being significantly increased following THA regardless of age, gender, BMI, previous surgery, primary diagnosis, and lifestyle. Key words: Hip Arthroplasty, Multicenter Study, Short Stem, Brevius CLS, Blood Ion Levels.

Introduction

The CLS® Brevius™ Stem with Kinectiv® Technology (also referred to as CLS Brevius Kinectiv Stem) is a straight, cementless stem based on the successful anchoring philosophy of the CLS Spotorno Stem. To be more bone-conserving, the stem was distally shortened by 20% compared to the CLS Spotorno Stem. The proximal fixation principle of the CLS Spotorno Stem, with its three-dimensional taper and longitudinal ribs, demonstrated excellent clinical long-term results and remains unchanged in the CLS Brevius Kinectiv Stem. To restore individual patients’ anatomies more accurately, the CLS Brevius Stems were fused with the existing Zimmer Kinectiv Modular Neck Technology. The modularity facilitates head center restoration and, thus, soft-tissue balancing by allowing the adjustment of leg length, offset, and ante-retroversion intraoperatively and independently from each other, without affecting proximal stem fit [1–4]. However, a modular system may lead to several complications, such as stress fractures or stem-neck dissociation, in particular during surgery [5–7]. Another major concern is related to local and systemic metal ion release [8].

The Kinectiv Technology Necks have been available on the market since 2007 with the M/L Taper Kinectiv Hip Stem, with good short-term clinical results, as reported by Duwelius et al. [9]. Comprehensive preclinical testing (including corrosion...
tests, fatigue tests, and pull-off tests) has been performed to ensure the mechanical and biological safety of the CLS Brevius Kinectiv Stem [10]. Currently, only one clinical study analyzes outcomes using the CLS Brevius Kinectiv Stem [11].

The primary purpose of this study was to analyze the implant survival and revision rate; the secondary aim was to evaluate clinical (pain and functional performances, subject health status) and radiographic parameters (radioluencies, osteolysis, hypertrophy, subsidence, etc.). Finally, safety was assessed by monitoring the frequency and incidence of adverse events (AEs), serious adverse events (SAEs), adverse device effects (ADEs), and serious adverse device effects (SADEs) and analysis of metal ion concentration in the blood.

Material and methods

Study design

This study is a multicenter (IRCCS Istituto Ortopedico Galeazzi, IRCCS Istituto Ortopedico Rizzoli, SPSK im. Prof. A. Grucy, HUA, DuPage Medical Group Ltd), prospective, non-controlled, consecutive cohort post-market clinical follow-up study involving five orthopedic surgeons (JG, JC, AT, NU, LL) skilled in THA procedures and experienced with the implant used in this study. The Ethics Committee (EC) approval for each site was obtained for this study. The study was conducted following the STROBE checklist for cohort studies and has been registered in the Clinical Trial Registry (NCT03410940, www.clinicaltrials.gov) [12].

All the subjects signed an informed consent process, and the EC approved written informed consent prior to study enrolment. Clinical and radiological follow-up evaluations were conducted before surgery and then at 6 months from hospital discharge and at 1, 2, 3, and 5 years (± 2 months) post-surgery. Metal ion (whole blood titanium and aluminum) analysis was performed in 2 centers (IRCCS Istituto Ortopedico Galeazzi and IRCCS Istituto Ortopedico Rizzoli) pre-operatively, 6 months, 1 year, 2 years, and 5 years post-operatively. Furthermore, implant survival was calculated during the whole follow-up.

Study population

The study population comprised a consecutive cohort of males and females who qualified for unilateral or bilateral primary THA following the inclusion criteria: minimum age of 18 years; severe hip pain and disability requiring primary unilateral or bilateral THA based on physical exam and medical history; able to cooperate in the required post-operative therapy; able to complete scheduled follow-up evaluations as described in the Informed Consent.

Exclusion Criteria: unable to give consent or to comply with the follow-up program; total prosthetic hip replacement device (including surface replacement arthroplasty, endoprosthesis, etc.) or femoral and/or acetabular osteosynthesis of the affected hip joint(s); the patient is a prisoner/mentally incompetent or unable to understand what participation in the study entails/a known alcoholic or drug abuser/anticipated to be non-compliant/pregnant; the presence of acute, chronic local or systemic infections; severe muscular, neural or vascular diseases that endanger the success of the procedure; lack of bony structures proximal or distal to the joint, so that good anchorage of the implant is unlikely or impossible; total or partial absence of the muscular or ligamentous apparatus; allergy to the implanted material, above all to metal (e.g., Vanadium); local bone tumors and/or cysts; skeletal immaturity.

A total of 222 patients were enrolled in the study, among which 106 were female (47.7%), and 116 were male (52.3%), with a mean age of 60.8 ± 13.2 years and mean BMI of 27.3 ± 4.5. Mean surgical time was 69.4 ± 19.9 min. The pre-operative diagnosis was primarily osteoarthritis in 178 patients (80.2%), avascular necrosis in 20 (9.0%), post-traumatic arthritis in 4 (1.8%), and other in 20 (9.0%). In 94 cases, a posterolateral or anterior approach was performed (42.4%), while in 34, a direct lateral approach was performed (15.2%). The detailed pre-operative and surgical data are presented in the Appendix (Tables A.1–A.12).

Study outcome measures/endpoints

Survivorship

The primary endpoint is defined as the implant survival (assessed by complete or partial revision of the device) [13].

Clinical outcomes

The outcome of the treatment was assessed through the following patient-reported outcome measure scores: pain and functional performance (Harris Hip Score [HHS], University of California, Los Angeles [UCLA] Activity Score, Oxford Hip Score) [14, 15] and subject quality-of-life (EQ-5D) [16].

Radiographic assessment

Radiographic assessment was performed in each center by a skilled musculoskeletal radiologist and evaluated in each patient restoration of anatomy, radioluencies, osteolysis, hypertrophy, subsidence, and bone stock changes [17].

Adverse events

Adverse events (AEs) were defined as an undesirable clinical development in a participant who was not present at baseline or increased in severity after treatment. AEs were assessed and graded in regards to severity:

Mild: awareness of a sign or symptom which does not interfere with the participants’ usual daily activity and/or is transient, resolving with the use of simple interventions, including simple analgesia.

Moderate: interferes with the participants’ usual daily activity and/or requires symptomatic treatment, including regular analgesia (i.e., opioid analgesia).

Severe: symptom(s) causing severe discomfort with significant impact on the participants’ usual daily activity.

Non-severe include a known alcoholic or drug abuser/anticipated to be non-compliant/pregnant; the presence of acute, chronic local or systemic infections; severe muscular, neural or vascular diseases that endanger the success of the procedure; lack of bony structures proximal or distal to the joint, so that good anchorage of the implant is unlikely or impossible; total or partial absence of the muscular or ligamentous apparatus; allergy to the implanted material, above all to metal (e.g., Vanadium); local bone tumors and/or cysts; skeletal immaturity.

A total of 222 patients were enrolled in the study, among which 106 were female (47.7%), and 116 were male (52.3%), with a mean age of 60.8 ± 13.2 years and mean BMI of 27.3 ± 4.5. Mean surgical time was 69.4 ± 19.9 min. The pre-operative diagnosis was primarily osteoarthritis in 178 patients (80.2%), avascular necrosis in 20 (9.0%), post-traumatic arthritis in 4 (1.8%), and other in 20 (9.0%). In 94 cases, a posterolateral or anterior approach was performed (42.4%), while in 34, a direct lateral approach was performed (15.2%). The detailed pre-operative and surgical data are presented in the Appendix (Tables A.1–A.12).

Study outcome measures/endpoints

Survivorship

The primary endpoint is defined as the implant survival (assessed by complete or partial revision of the device) [13].

Clinical outcomes

The outcome of the treatment was assessed through the following patient-reported outcome measure scores: pain and functional performance (Harris Hip Score [HHS], University of California, Los Angeles [UCLA] Activity Score, Oxford Hip Score) [14, 15] and subject quality-of-life (EQ-5D) [16].

Radiographic assessment

Radiographic assessment was performed in each center by a skilled musculoskeletal radiologist and evaluated in each patient restoration of anatomy, radioluencies, osteolysis, hypertrophy, subsidence, and bone stock changes [17].

Adverse events

Adverse events (AEs) were defined as an undesirable clinical development in a participant who was not present at baseline or increased in severity after treatment. AEs were assessed and graded in regards to severity:

Mild: awareness of a sign or symptom which does not interfere with the participants’ usual daily activity and/or is transient, resolving with the use of simple interventions, including simple analgesia.

Moderate: interferes with the participants’ usual daily activity and/or requires symptomatic treatment, including regular analgesia (i.e., opioid analgesia).

Severe: symptom(s) causing severe discomfort with significant impact on the participants’ usual daily activity.
Serious: an unexpected medical incident which requires hospitalization, results in long-term disability, is life-threatening or results in death [18].

Furthermore, metal ion concentration in the blood was measured.

Statistical analysis

The mean of clinical scores (UCLA, EQ-5D, HHS, OXFORD) and laboratory findings (aluminum and titanium) were compared at different time assessments with a repeated measure analysis of variance. A Toeplitz, autoregressive, or unstructured covariance matrix within the subject residuals was selected according to how well of a fit it was with the model (Akaike Information Criterion). The Wilcoxon signed-rank test was preferred in case of deviation from the assumptions of the model.

A secondary analysis was conducted to assess the variations by gender, age, BMI, primary diagnosis (osteoarthritis vs. others), tobacco and alcohol consumption, femoral size, taper (straight vs. other), previous surgery, and surgical approach (posterolateral vs. anterolateral vs. direct lateral). The age, BMI, and femoral size were included in the repeated measure model as binary variables dichotomized at their average rounded value. When a non-parametric test was preferred, the Kruskal–Wallis and Wilcoxon–Mann–Whitney tests were performed to compare means of different groups at the same time period (within time comparison), while the Wilcoxon signed-rank test was performed to compare means of the same group at different time periods (within-group comparison). Furthermore, the correlation among variables was calculated and tested using the Pearson or Spearman rank correlation according to the distribution of the variables. Finally, the proportions of radiographic diagnosis/results at different time assessments were compared with a Fisher exact test or a Chi-squared test.

The Bonferroni correction was used for multiple comparisons. A two-tailed p-value less than 0.05 was considered statistically significant. The statistical analyses were performed using SAS 9.4.

Results

Implant survival

No revisions were performed during the follow-up period.

Clinical outcomes

All the clinical parameters showed overall improvement over time measured with ANOVA for repeated measures; furthermore, clinical scores showed a statistically significant improvement at 5 years with respect to pre-operative value (p < 0.001). The detailed results are reported in Table 1.

Radiographic results

The only significant radiographic changes were regarding the percentage of patients with acetabular radiolucency at 3 and 5 years (p < 0.05). The detailed results are reported in Table 2. Figure 1 shows radiographic results at 5-year follow-up with no signs of mobilization or osteolysis.

Subgroup analyses

Gender

Both male and female groups showed significant improvement in all clinical scores and their respective pre-operative value (p < 0.05). The female group showed a lower UCLA and EQ-5D score with respect to the male group at the pre-operative visit and at 6 months and 5-year follow-up (p < 0.05). For the HHS score, the female group showed lower value at pre-operative follow-up and at 6 months and 1 year (p < 0.05), while for the Oxford score, the female group showed lower scores at pre-operative follow-up and then at 6 months,
Table 2. Radiographic assessment at each follow-up; comparison by time assessment was performed using Bonferroni adjusted p-value.

| Follow up visit | Anteroposterior Femoral Periosteal Cortical Hypertrophy | Lateral Femoral Periosteal Cortical Hypertrophy | Anteroposterior Femoral Bone Condensation | Lateral Femoral Bone Condensation | Anteroposterior Femoral Sclerotic Halo for zone | Anteroposterior Acetabular Radiolucency | Heterotopic Ossification | Anteroposterior Femoral Radioluency |
|----------------|--------------------------------------------------------|-----------------------------------------------|------------------------------------------|-----------------------------------|---------------------------------------------|----------------------------------------|-------------------------------|-------------------------------|
|                | n (%) | n (%) | Total | n (%) | n (%) | Total | n (%) | n (%) | Total | n (%) | n (%) | Total |
| 6 Month        | 1 (0.5%) | 191 (99.5%) | 192 (100.0%) | 0 | 192 (100.0%) | 192 (100.0%) | 0 | 192 (100.0%) | 192 (100.0%) | 0 | 192 (100.0%) | 192 (100.0%) |
| 1 Year         | 1 (0.6%) | 176 (99.4%) | 177 (100.0%) | 1 Year | 0 | 177 (100.0%) | 177 (100.0%) | 2 | 141 (98.6%) | 143 (100.0%) | 3 | 138 (97.9%) | 141 (100.0%) |
| 2 Year         | 5 (3.5%) | 138 (96.5%) | 143 (100.0%) | 2 Year | 2 (1.4%) | 141 (98.6%) | 143 (100.0%) | 3 | 138 (97.9%) | 141 (100.0%) | 3 | 138 (97.9%) | 141 (100.0%) |
| 3 Year         | 5 (3.5%) | 136 (96.5%) | 141 (100.0%) | 3 Year | 3 (2.1%) | 138 (97.9%) | 141 (100.0%) | 5 | 73 (96.1%) | 76 (100.0%) | 5 Year | 5 (3.5%) | 72 (94.7%) | 76 (100.0%) |
| 4 Year         | 4 (5.3%) | 72 (94.7%) | 76 (100.0%) | 5 Year | 3 (3.9%) | 73 (96.1%) | 76 (100.0%) | 6 Month | 0 | 192 (100.0%) | 192 (100.0%) |
| 5 Year         | 0 | 192 (100.0%) | 192 (100.0%) | 1 Year | 4 (2.3%) | 173 (97.7%) | 177 (100.0%) | 2 Year | 3 (2.1%) | 140 (97.9%) | 143 (100.0%) |
|                | 0 | 177 (100.0%) | 177 (100.0%) | 2 Year | 2 (1.4%) | 141 (98.6%) | 143 (100.0%) | 3 Year | 3 (2.1%) | 138 (97.9%) | 141 (100.0%) |
|                | 2 Year | 5 (3.5%) | 136 (96.5%) | 141 (100.0%) | 5 Year | 0 | 192 (100.0%) | 192 (100.0%) | 1 Year | 2 (1.1%) | 175 (98.9%) | 177 (100.0%) |
|                | 1 Year | 4 (2.3%) | 173 (97.7%) | 177 (100.0%) | 2 Year | 3 (2.1%) | 140 (97.9%) | 143 (100.0%) | 2 Year | 0 | 143 (100.0%) | 143 (100.0%) |
|                | 3 (2.1%) | 138 (97.9%) | 141 (100.0%) | 5 Year | 5 (3.5%) | 72 (94.7%) | 76 (100.0%) | 3 Year | 0 | 140 (99.3%) | 141 (100.0%) |
|                | 0 | 192 (100.0%) | 192 (100.0%) | 5 Year | 1 (0.7%) | 140 (99.3%) | 141 (100.0%) | 5 Year | 1 (1.3%) | 75 (98.7%) | 76 (100.0%) |
| 3 Year         | 3 (3.9%) | 73 (96.1%) | 76 (100.0%) | 5 Year | 3 (3.9%) | 73 (96.1%) | 76 (100.0%) | 6 Month | 12 (6.3%) | 180 (93.8%) | 192 (100.0%) |
|                | 8 (4.9%) | 170 (95.1%) | 177 (100.0%) | 1 Year | 24 (13.6%) | 153 (86.4%) | 177 (100.0%) | 2 Year | 27 (18.9%) | 116 (81.1%) | 143 (100.0%) |
| 5 Year         | 0 | 177 (100.0%) | 177 (100.0%) | 3 Year | 22 (15.6%) | 119 (84.4%) | 141 (100.0%) | 5 Year | 13 (71.1%) | 63 (28.9%) | 76 (100.0%) |
|                | 8d (10.5%) | 68d (89.5%) | 76 (100.0%) | Anteroposterior Femoral Sclerotic Halo for zone | 6 Month | 4 (2.1%) | 188 (97.9%) | 192 (100.0%) |
| 3 Year         | 8 (5.7%) | 133 (94.3%) | 141 (100.0%) | 1 Year | 6 (3.4%) | 171 (96.6%) | 177 (100.0%) | 2 Year | 6 (4.2%) | 137 (95.8%) | 143 (100.0%) |
|                | 3 (3.9%) | 73 (96.1%) | 76 (100.0%) | 3 Year | 5 (3.5%) | 136 (96.5%) | 141 (100.0%) | 5 Year | 6 (7.9%) | 70 (92.1%) | 76 (100.0%) |
| 5 Year         | 4 (5.3%) | 72 (94.7%) | 76 (100.0%) | 5 Year | 3 (3.9%) | 73 (96.1%) | 76 (100.0%) |

* Significant difference (p < 0.05) by time; = not evaluated.
  a Statistical significant difference versus 6-month value.
  b Statistical significant difference versus 1-year value.
  c Statistical significant difference versus 2-year value.
  d Statistical significant difference versus 3-year value.

1 and 2-year follow-up. No difference among groups was noted regarding aluminum and titanium ion levels. The detailed results are reported in Table 3.

Figure 1. Anteroposterior pelvis X-ray showing CLS Brevius Kinectiv Stem 5 years after surgery with no signs of mobilization or osteolysis.

Age

Analysis by age showed a significant improvement in all clinical scores with respect to the pre-operative value for both groups (< 60 years and ≥ 60 years) (p < 0.05). Furthermore, the older group showed lower UCLA scores at 1, 2, and 3 years (p < 0.05), lower HHS at 3 years, and lower Oxford scores at 1 and 3 years. The titanium ion levels were lower in the older group at pre-operative evaluation (p < 0.05). The detailed results are reported in Table 4.

BMI

According to the BMI analysis, significant improvement was shown in all clinical scores with respect to the pre-operative value for both groups (BMI < 27 and BMI ≥ 27) (p < 0.05). The only clinical difference was noted for the UCLA score at a 2-year follow-up (p < 0.05). The detailed results are reported in the Appendix (Tables A.1–A.12).

Primary diagnosis

Analysis by primary diagnosis showed significant improvement in all the clinical scores with respect to the pre-operative value for both groups (p < 0.05). Furthermore, the patients with primary osteoarthritis showed higher pre-operative values for UCLA, EQ-5D, Oxford and HHS (p < 0.05). A higher value of Oxford score was also found at a 3-year follow-up (p < 0.05). The detailed results are reported in the Appendix (Tables A.1–A.12).

Tobacco and alcohol consumption

Both tobacco and alcohol consumers showed an overall improvement in all clinical scores with respect to the pre-operative value (p < 0.05). No other statistically significant differences with non-consumers were noted (p > 0.05). The detailed results are reported in the Appendix (Tables A.1–A.12).
Scores and laboratory findings are presented as mean ± SD (n).
* Significant difference (p < 0.05) by time; = not evaluated.
a Statistical significant difference versus Preop value.
b Statistical significant difference versus 6-month value.
carb Statistical significant difference versus 1-year value.

### Femoral size

Both groups divided based on femoral size (femoral size < 10 and femoral size ≥ 10) showed an overall improvement in all the clinical scores with respect to the pre-operative value (p < 0.05). The detailed results are reported in the Appendix (Tables A.1–A.12).

### Complications

Only two hip-related complications were reported: in one case, hip pain, swelling, and wound redness after 3 weeks of

### Previous surgery

The patients with previous hip surgery reported similar results as the patients who underwent surgery for the first time and showed an overall improvement in all clinical scores with respect to the pre-operative value (p < 0.05). The detailed results are reported in the Appendix (Tables A.1–A.12).
the index procedure, while in the other case, psoas tendonitis was resolved with one corticosteroid shot. Aluminum and titanium showed no variation for repeated measures at different time points \((p > 0.05)\). No revisions were performed during the follow-up period.

**Correlations**

The significant correlations with surgical time are reported in Table 5. The significant correlation between sociodemographic, surgical characteristics data, clinical scores, and laboratory values are reported in the Appendix (Tables A.1–A.12).

**Discussion**

To our knowledge, this is the first and largest multicentric short- to mid-term follow-up study on the CLS Brevius Kinectiv Stem, with 222 implants stratified by age, gender, BMI, primary diagnosis, previous surgery, and lifestyle. Our results demonstrated excellent implant survivorship with no revision surgeries; overall, the patients demonstrated statistically and clinically significant improvements in all clinical parameters (Harris Hip Score, Oxford Hip Score, UCLA, and EQ-5D) as well as improvements in multiple radiographic measurements at the final follow-up. There are several limitations to this study: first of all, the short- to mid-term follow-up, and, furthermore, the lack of a control group to assess clinical and radiological differences analyzing alternative arthroplasty implants. Furthermore, at a 5-year follow-up, many patients were lost. Another limitation of the study is the lack of specifying the previous surgery performed in some patients, but this was indifferent, as between the two groups, there were no differences in all follow-up. This finding is also confirmed by the literature, which shows that after several types of surgery, the clinical results for hip replacement are excellent [19–21].

Another limitation of the study is the different surgical approaches used, but also, in this case, the literature shows that the approach does not affect the final result therefore, it will not be a bias for our study [22–25].

Currently, no multi-centre study has been performed regarding the clinical and radiological results of CLS Brevius Kinectiv Stem; multi-centre collaboration can result in higher rates of patient enrolment than single-center trials, thereby generating larger studies of shorter duration. A contrasting result that emerged from the study is the low number of complications reported during the follow-up study. This can be due to the multicentric nature of the study, where the enrolment of patients in several sites enhances the generalizability of the results to similar patients in similar settings. However, at the same time, the wide variation in organizational issues among sites may influence patient outcomes [26–28], limiting the extrapolation of the results of multicenter studies to other patients with different case mixes. In multicenter studies, a rigorous protocol is used to ensure uniform data collection; however, heterogeneity in clinical practice among different centers may be a major confounding factor in interpreting the results of these studies. Despite the possible bias of a multicenter study and the different experiences of individual surgeons, the results reported were similar, ranging from good to excellent. In this scenario, to avoid mistakes resulting from the differences in the surgeons’ experiences, a key role is played by the learning curve. In fact, different approaches have been taken by different surgeons, creating a possible bias. In 2016, den Hartog et al. evaluated the literature regarding the anterior approach in comparison to other approaches, investigating if there is a learning curve for the anterior approach [29]. There was strong evidence that showed no difference in component placement between the anterior approach and other approaches. Also, strong evidence for faster post-operative recovery and less need for assistive devices after the anterior approach was found. All the other studied parameters demonstrated conflicting evidence. Although the learning curve for the anterior approach is not yet clear, this learning curve should not be neglected.

Similarly, Padilla et al. evaluated the learning curve among the THA recipients using a novel short-stem hip prosthesis, concluding that this stem model is a safe alternative for THA, reporting a fracture incidence of 2.9% among patients [30]. However, surgeons should remain cautious when utilizing new implant systems and expect a learning curve estimated at 30 cases.

Currently, only one study in the literature reported clinical results with this stem, reporting a series of 155 patients at a mean follow-up of 32 months. The mean HHS, it was reported,

| Variables correlated with surgical time | Rho   | \(p\)-value | \(N\) |
|----------------------------------------|-------|-------------|------|
| Blood loss                             | 0.6989| \(<.0001^{*}\) | 222  |
| Clinical scores                        |       |             |      |
| 1 Year                                 | 0.15  | 0.0423\(^{*}\) | 178  |
| 5 Year                                 | \(-0.25\) | 0.0322\(^{*}\) | 76   |
| EQSD                                   |       |             |      |
| Preop                                  | \(-0.25\) | 0.0002\(^{*}\) | 222  |
| 6 Month                                | \(-0.36\) | \(<.0001^{*}\) | 194  |
| HHS                                    |       |             |      |
| Preop                                  | \(-0.24\) | 0.0003\(^{*}\) | 222  |
| 1 Year                                 | \(-0.26\) | 0.0005\(^{*}\) | 177  |
| 2 Year                                 | \(-0.34\) | \(<.0001^{*}\) | 144  |
| 3 Year                                 | \(-0.26\) | 0.0015\(^{*}\) | 142  |
| 6 Month                                | \(-0.20\) | 0.0051\(^{*}\) | 195  |

\(^{*}\)Significant difference \((p < 0.05)\).
improved from 32 points pre-operatively to 92 points at the final follow-up, while the stem survival rate was 99.4%. Overall, the results were excellent in 148 hips (87%), good in 14 hips (8.2%), fair in six hips (3.6%), and poor in two hips (1.2%). The intraoperative complications included a calcar fissure in three hips (1.7%). The correct femoral offset was reproduced in 97%, while the planned center of hip rotation was achieved in 98%. Only one hip underwent early stem revision; this was due to major subsidence [11].

Analyzing the results from the study of Graceffa et al. [11], we can confirm good to excellent results in almost all patients with a high rate of survival of the implant.

Despite these excellent outcomes, the major limitation of the CLS Spotorno Stem was that it had only three possible femoral-neck inclination angles (145°, 135°, and 125°) and five different lengths of the metallic femoral heads (–3.5 mm; 0 mm, +3.5 mm, 7 mm, and 10 mm); multiple combinations of these parameters allowed the correct center of hip rotation to be reproduced in many, but not all, cases [31–33].

However, the addition of a further interface (the modular femoral neck) might potentially be associated with complications such as stress fractures caused by corrosion [5, 34, 35] or stem-neck disassociation, in particular during dislocation reduction maneuvers [6]. Another major concern is the correlation between increased modularity and corrosion associated with titanium ion release under in vivo conditions [7], leading to local tissue infiltration and adverse periarticular tissue reactions [8]. For this reason, we decided to evaluate titanium and aluminum blood ion levels over time, and they also showed no significant increase at the 5-year follow-up.

The release of ions in the blood remains a big challenge for all hip surgeons. In 2013, Catalani et al. verified the correlation of vanadium levels among different matrices and assessed reference levels of the ion in a population of patients wearing well-functioning hip prostheses; they observed that the values in the serum were above the upper limit of the reference values in 42% of patients (29% in urine and 13% in whole blood) [36].

Additionally, Bistolfi et al. tried to establish if an increase in surface area can lead to a significant increase in systemic metal levels. Patients with trabecular titanium did not have significantly higher metal ion levels than patients with conventional cups for up to 2 years. A trend over time was statistically significant in blood and urine for aluminum and titanium concentrations [37].

These results appear in contrast with blood metal levels analyzed in our study, where no significant increase of aluminum and titanium was found in the entire follow-up; furthermore, no significant correlations were found between metal ions and complications or clinical scores, confirming the safety of the CLS Brevius Kinectiv Stem implant.

Analyzing the correlations, we found that several parameters directly correlated with surgical time, in particular blood loss and clinical scores. The operative time has frequently been implicated as a risk factor for complications, including infection, venous thromboembolism, and neurologic deficit after arthroplasty, and it remains a potentially modifiable variable that is of interest to surgeons and hospitals interested in quality improvement [38–41]. These findings have been confirmed by Duchman et al., who analyzed the American College of Surgeons National Surgical Quality Improvement Program data. The database queried from 2011 to 2013 demonstrated overall complications increasing in patients whose operative time was > 120 min (5.9%) compared to patients whose operative time < 60 min or 60–120 min (4.6% and 4.8%, respectively; p < 0.001). Wound complications, including surgical site infection, were also increased for procedures lasting >120 min. In a multivariable analysis, operative time exceeding 120 min remained an independent predictor of any complication and wound complication, with each 30-minute increase in operative time beyond 120 min further increasing risk.

Conclusions

The functional outcomes measured in this first prospective international multicenter study of the CLS Brevius Kinectiv Stem indicated that subject’s well-being significantly increased following THA regardless of age, gender, BMI, previous surgery, primary diagnosis, and lifestyle. Pain, functional measures, and health status exhibited statistically significant improvement maintained through the entire follow-up. The radiographic parameters also presented a low incidence of findings. Titanium and aluminum blood levels did not show a significant increase over time. Overall, the treatment of primary or secondary hip osteoarthritis using the CLS Brevius Kinectiv Stem resulted in reliable functional and radiological outcome improvement at short-term follow-up in this series.

Competing interests

The authors declare that they have no conflict of interest.

Funding

This study was funded by Zimmer-Biomet.

Ethical approval

The study received ethical approval, and the file is attached to the submission.
Consent to participate

Informed consent was obtained from all individual participants included in the study.

Consent to publish

Informed consent was obtained from all individual participants to publish anonymously the data.

Authors’ contributions

All authors contributed equally.

Availability of data and materials

Data are available under request to Zimmer-Biomet. Study Registration: Clinical Trial Registry – NCT03410940; www.clinicaltrials.gov.

References

1. Ceretti M, Falez F (2016) Modular titanium alloy neck failure in total hip replacement: analysis of a relapse case. SICOT J 2, 20.
2. Fontalis A, Epinette JA, Thaler M, Zagra L, Khanduja V, Haddad FS (2021) Advances and innovations in total hip arthroplasty. SICOT J 7, 26.
3. Kouyoumdjian P, Mansour J, Assi C, Caton J, Lustig S, Coulomb R (2020) Current concepts in robotic total hip arthroplasty. SICOT J 6, 45.
4. Ercan A, Sokkar SM, Schmid G, Filler TJ, Abdelkafy A, Jerosch J (2016) Periprosthetic bone density changes after MiniHip™ cementless femoral short stem: one-year results of dual-energy X-ray absorptiometry study. SICOT J 2, 40.
5. Skendzel JG, Blaha JD, Urquhart AG (2011) Total hip arthroplasty modular neck failure. J Arthroplasty 26(2), 338.e1–338.e4.
6. Fanuele J, Benini P (2007) Dissociation of the modular femoral stem from the metaphyseal sleeve during a total hip arthroplasty dislocation. J Arthroplasty 22(1), 140–142.
7. Kretzer JP, Jakubowicz E, Krachler M, Thomsen M, Heisel C (2009) Metal release and corrosion effects of modular neck total hip arthroplasty. Int Orthop 33(6), 1531–1536.
8. Jacobs JJ, Urban RM, Gilbert JL, Skipor AK, Black J, Jasty M, Galante JO (1995) Local and distant products from modularity. Clin Orthop Relat Res 319, 94–105.
9. Duwelius PJ, Hartzband MA, Burkhart R, Carnahan C, Blair S, Wu Y, Grunkemeier GL (2010) Clinical results of a modular neck hip system: hitting the "bull’s-eye" more accurately. Am J Orthop (Belle Mead NJ) 39(10 Suppl), 2–6.
10. ISO 7206–6:1992(E) (1992) Implants for surgery – Partial and total hip joint prostheses – Part 6: Determination of endurance properties of head and neck region of stemmed femoral components implants.
11. Graceffa A, Indelli PF, Latella L, Poli P, Fulco A, Marucci M. 2016. Clinical outcome of design modifications to the CLS Spotorno Stem in total hip replacement. Joints 4(3), 134–141.
12. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, STROBE Initiative. 2008. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 61(4), 344–349.
13. Foissery C, Fauverney M, Fary C, Servien E, Lustig S, Batailler C. 2020. Total hip arthroplasty performed by direct anterior approach – Does experience influence the learning curve? SICOT J 6, 15.
14. Nilsdotter A, Bremander A (2011) Measures of hip function and symptoms: Harris Hip Score (HHS), Hip Disability and Osteoarthritis Outcome Score (HOOS), Oxford Hip Score (OHS), Lequesne Index of Severity for Osteoarthritis of the Hip (LISOH), and American Academy of Orthopedic Surgeons (AAOS) Hip and Knee Questionnaire. Arthritis Care Res (Hoboken) 63(Suppl 11), S200–S207.
15. Turnbull GS, Scott CEH, MacDonald DJ, Breusch SJ (2019) Return to activity following revision total hip arthroplasty. Arch Orthop Trauma Surg 139(3), 411–421.
16. Rabin R, de Charro F (2001) EQ-5D: a measure of health status from the EuroQol Group. Ann Med 33(5), 337–343.
17. Agarwala S, Vijayvargiya M. 2021. Predictive factors affecting long-term survivorship of ASR metal-on-metal total hip arthroplasty. SICOT J 7, 51.
18. Willhuber GC, Stagnaro J, Petracchi A, Monzon DG, Bonorino JA, Zamboni DT, Bilbao F, Albergo J, Puzio NS, Bongiovanni S (2018) Short-term complication rate following orthopedic surgery in a tertiary care center in Argentina. SICOT J 4, 26.
19. Stibolt RD Jr, Patel HA, Huntley SR, Lehtonen EJ, Shah AB, Naranje SM (2018) Total hip arthroplasty for posttraumatic osteoarthritis following acetabular fracture: A systematic review of characteristics, outcomes, and complications. Chin J Traumatol 21(3), 176–181.
20. Yuan BJ, Abdel MP, Cross WW, Berry DJ (2017) Hip arthroplasty after surgical treatment of intertrochanteric hip fractures. J Arthroplasty 32(11), 3438–3444.
21. Jain MV, Rajpura A, Kumar VS, Shaw D, Najjar MA, Kalsi NK, Hakimi M, Selvaratnam V, Jackson R, Board TN (2019) Functional outcome of total hip arthroplasty after a previous hip arthroscopy: a retrospective comparative cohort study. Hip Int 29(4), 363–367.
22. Higgins BT, Barlow DR, Heagerty NE, Lin TJ (2015) Anterior vs. posterior approach for total hip arthroplasty, a systematic review and meta-analysis. J Arthroplasty 30(3), 419–434.
23. Moerenhout K, Derome P, Lafrance M, Tardif C, LeBlanc M, Gaudreault M, Fortier M, Bessette P, Petrucci M, LeBlanc G, Girard A, Pare G (2015) Does experience in anterior approach total hip arthroplasty: patient-reported and functional outcomes in the early postoperative period. Hip Int 30(6), 596–601.
24. Baba T, Homma Y, Jinnai Y, Tanabe H, Banno S, Watari T, Haddad FS (2021) Advances and innovations in total hip arthroplasty. SICOT J 7, 51.
25. Higgins BT, Barlow DR, Heagerty NE, Lin TJ (2015) Anterior vs. posterior approach for total hip arthroplasty, a systematic review and meta-analysis. J Arthroplasty 30(3), 419–434.
26. Moorenout K, Bremander A, Monzon DG, Bonorino JA, Zamboni DT, Bilbao F, Albergo J, Puzio NS, Bongiovanni S (2018) Short-term complication rate following orthopedic surgery in a tertiary care center in Argentina. SICOT J 4, 26.
27. Stibolt RD Jr, Patel HA, Huntley SR, Lehtonen EJ, Shah AB, Naranje SM (2018) Total hip arthroplasty for posttraumatic osteoarthritis following acetabular fracture: A systematic review of characteristics, outcomes, and complications. Chin J Traumatol 21(3), 176–181.
28. Yuan BJ, Abdel MP, Cross WW, Berry DJ (2017) Hip arthroplasty after surgical treatment of intertrochanteric hip fractures. J Arthroplasty 32(11), 3438–3444.
29. Jain MV, Rajpura A, Kumar VS, Shaw D, Najjar MA, Kalsi NK, Hakimi M, Selvaratnam V, Jackson R, Board TN (2019) Functional outcome of total hip arthroplasty after a previous hip arthroscopy: a retrospective comparative cohort study. Hip Int 29(4), 363–367.
30. Higgins BT, Barlow DR, Heagerty NE, Lin TJ (2015) Anterior vs. posterior approach for total hip arthroplasty, a systematic review and meta-analysis. J Arthroplasty 30(3), 419–434.
31. Moerenhout K, Derome P, Lafrance M, Tardif C, LeBlanc M, Gaudreault M, Fortier M, Bessette P, Petrucci M, LeBlanc G, Girard A, Pare G (2015) Does experience in anterior approach total hip arthroplasty: patient-reported and functional outcomes in the early postoperative period. Hip Int 30(6), 596–601.
32. Sandy J, Kilpatrick N, Persson M, Bessel A, Waylen A, Ness A, Ireland A (2011) Why are multi-centre clinical observational studies still so difficult to run? Br Dent J 211(2), 59–61.
27. Dimick JB, Pronovost PJ, Heitmiller RF, Lipsett PA (2001) Intensive care unit physician staffing is associated with decreased length of stay, hospital cost, and complications after esophageal resection. Crit Care Med 29(4), 753–758.

28. Pronovost PJ, Jenckes MW, Dorman T, Garrett E, Breslow MJ, Rosenfeld BA, Lipsett PA, Bass E (1999) Organizational characteristics of intensive care units related to outcomes of abdominal aortic surgery. JAMA 281(14), 1310–1317.

29. den Hartog YM, Mathijssen NM, Vehmeijer SB (2016) The less invasive anterior approach for total hip arthroplasty: a comparison to other approaches and an evaluation of the learning curve - a systematic review. Hip Int 26(2), 105–120.

30. Padilla JA, Anoushiravani AA, Feng JE, Schwarzkopf R, Slover J, Marwin S (2019) The learning curve following adoption of a novel short-stem prosthesis in total hip arthroplasty: implications on short-term patient outcomes. Eur J Orthop Surg Traumatol 29(4), 819–825.

31. Mert M, Ermutlu C, Kovalak E, Ünkar E, Okur SC (2019) Long term survival analysis of cementless Spotorno femoral stem in young patients. Acta Orthop Traumatol Turc 53(1), 19–23.

32. Zang J, Uchiyama K, Moriya M, Li Z, Fukushima K, Yamamoto T, Takahira N, Takaso M, Liu J, Feng W (2018) Long-term clinical and radiographic results of the cementless Spotorno stem in Japanese patients: A more than 15-year follow-up. J Orthop Surg (Hong Kong) 26(1), 2309499017750310.

33. Evola FR, Evola G, Graceffa A, Sessa A, Pavone V, Costarella L, Sessa G, Avondo S (2014) Performance of the CLS Spotorno uncemented stem in the third decade after implantation. Bone Joint J 96-B(4), 455–461.

34. Dangles CJ, Altstetter CJ (2010) Failure of the modular neck in a total hip arthroplasty. J Arthroplasty 25(7), 1169.e5–1169.e7.

35. Ellman MB, Levine BR (2013) Fracture of the modular femoral neck component in total hip arthroplasty. J Arthroplasty 28(1), 196.e1–196.e5.

36. Catalani S, Stea S, Beraudi A, Gilberti ME, Bordini B, Toni A, Apostoli P (2013) Vanadium release in whole blood, serum and urine of patients implanted with a titanium alloy hip prosthesis. Clin Toxicol (Phila) 51(7), 550–556.

37. Bistolfi A, Cimino A, Lee GC, Ferracini R, Maina G, Berchialla P, Massaza G, Massè A (2018) Does metal porosity affect metal ion release in blood and urine following total hip arthroplasty? A short term study Hip Int 28(5), 522–530.

38. Namba RS, Inacio MC, Paxton EW (2013) Risk factors associated with deep surgical site infections after primary total knee arthroplasty: an analysis of 56,216 knees. J Bone Joint Surg Am 95(9), 775–782.

39. Peersman G, Laskin R, Davis J, Peterson MG, Richart T (2006) Prolonged operative time correlates with increased infection rate after total knee arthroplasty. HSS J 2(1), 70–72.

40. Kurtz SM, Ong KL, Lau E, Bozic KJ, Berry D, Parvizi J (2010). Prosthetic joint infection risk after TKA in the Medicare population. Clin Orthop Relat Res 468(1), 52–56.

41. Jaffer AK, Barsoum WK, Krebs V, Hurbanek JG, Morra N, Brotman DJ (2005) Duration of anesthesia and venous thromboembolism after hip and knee arthroplasty. Mayo Clin Proc 80(6), 732–738.

42. Duchman KR, Pugely AJ, Martin CT, Gao Y, Bedard NA, Callaghan JJ (2017) Operative time affects short-term complications in total joint arthroplasty. J Arthroplasty 32(4), 1285–1291.

43. Surace P, Sultan AA, George J, Samuel LT, Khlopas A, Molloy RM, Stearns KL, Mont MA (2019) The association between operative time and short-term complications in total hip arthroplasty: An analysis of 89,802 surgeries. J Arthroplasty 34(3), 426–432.

44. Pluot E, Davis ET, Revell M, Davies AM, James SL (2009) Hip arthroplasty. Part 2: normal and abnormal radiographic findings. Clin Radiol 64(10), 961–971.
## Appendix

### Table A.1. Different femoral head used.

| Femoral Head                             | N   | %    |
|------------------------------------------|-----|------|
| Biolox Delta Ceramic                      | 169 | 76.1%|
| Centerpulse CoCr                         | 12  | 5.4% |
| Cerasul Ceramic                           | 4   | 1.8% |
| Prostak 12/14 Neck Taper                 | 7   | 3.2% |
| Sulox Ceramic, 12/14 Taper               | 3   | 1.4% |
| VerSys CoCr 12/14 Taper                  | 26  | 11.7%|
| Not available                             | 1   | 0.4% |

### Table A.2. Acetabular cup used.

| Acetabular Cup                           | N   | %    |
|------------------------------------------|-----|------|
| ALLOCASSIC VARIALL UNCEMENTED            | 14  | 6.3% |
| Allofit IT, Prostak                      | 8   | 3.6% |
| Allofit IT, Prostak with Screw Holes     | 2   | 0.9% |
| Allofit Uncemented                       | 33  | 14.8%|
| Allofit Uncemented with Screw Holes      | 25  | 11.3%|
| Continuum TM CLUSTER HOLES POROUS        | 89  | 40.2%|
| Continuum TM MULTI HOLES POROUS          | 2   | 0.9% |
| TM Modular, Cluster-Holed                | 8   | 3.6% |
| Trilogo, Cluster-Holed, F/M              | 40  | 18.0%|
| Not Available                            | 1   | 0.4% |

### Table A.3. Acetabular liner used.

| Acetabular Liner                         | N   | %    |
|------------------------------------------|-----|------|
| Alpha Durasul, Hooded                    | 22  | 9.9% |
| Alpha Durasul, Standard                  | 36  | 16.2%|
| Biolox delta Taper Liner                 | 45  | 20.4%|
| Cerasul Insert                            | 1   | 0.4% |
| Gamma Cerasul Insert                      | 8   | 3.6% |
| Gamma Durasul Insert                      | 5   | 2.3% |
| LONGEVITY IT, XLPE, Elevated Rim         | 1   | 0.4% |
| LONGEVITY IT, XLPE, Neutral              | 4   | 1.8% |
| LONGEVITY IT, XLPE, Offset               | 2   | 0.9% |
| Trilogy Longevity, XLPE, 3.5 mm Offset   | 17  | 7.7% |
| Trilogy Longevity, XLPE, 3.5 mm Offset, 10 Degree Elevated Rim | 31 | 13.9% |
| VIVACIT-E NEUTRAL                        | 49  | 22.1%|
| Not available                            | 1   | 0.4% |

### Table A.4. Kinectiv neck offset used.

| OFFSET       | N   | %     |
|--------------|-----|-------|
| EXT          | 80  | 36.0% |
| RED          | 15  | 6.7%  |
| STD          | 111 | 50.0% |
| XEXT         | 14  | 6.3%  |
| XRED         | 1   | 0.5%  |
| Not available| 1   | 0.5%  |

### Table A.5. Kinectiv neck version.

| Version       | N   | %     |
|---------------|-----|-------|
| Anteverted    | 15  | 6.8%  |
| Retroverted   | 11  | 4.9%  |
| Straight      | 195 | 87.8% |
| Not available | 1   | 0.5%  |
Table A.6. Subgroup analysis by BMI.

| Follow up visit | Mean value and comparison within time period | Comparison by time within subgroups (Bonferroni adjusted p-value) |
|-----------------|---------------------------------------------|----------------------------------------------------------------|
|                 | BMI < 27 | BMI ≥ 27 |               | BMI < 27 | BMI ≥ 27 |               |               |               |
|                 | Unadjusted mean ± SD (n) | Unadjusted mean ± SD (n) | p-value | Preop 6 Month 1 Year 2 Year 3 Year | Preop 6 Month 1 Year 2 Year 3 Year |               |               |
| UCLA            |          |          |            |          |          |            |          |
| Preop           | 3.9 ± 1.6 (113) | 3.8 ± 1.6 (109) | 0.4800 | – – – – – – | – – – – – – |               |               |
| 6 Month         | 3.5 ± 1.4 (101) | 5.5 ± 1.4 (94) | 0.9481 | <.0001* | – – – – – – | – – – – – – |               |               |
| 1 Year          | 6.1 ± 1.6 (86) | 5.7 ± 1.6 (92) | 0.0531 | <.0001* | 0.0054* | – – – – – – | – – – – – – |               |
| 2 Year          | 6.4 ± 1.6 (73) | 5.8 ± 1.5 (72) | 0.0078* | <.0001* | <.0001* | 1.0000 | – – – – – – |               |
| 3 Year          | 6.4 ± 1.6 (71) | 6.0 ± 1.5 (72) | 0.0876 | <.0001* | <.0001* | 1.0000 | 1.0000 | – – – – – – |
| 5 Year          | 6.7 ± 1.3 (42) | 6.1 ± 1.5 (34) | 0.0895 | <.0001* | 0.0020* | 1.0000 | 1.0000 | 1.0000 | 1.0000 |
| EQ5D            |          |          |            |          |          |            |          |
| Preop           | 0.5 ± 0.3 (113) | 0.4 ± 0.3 (109) | 0.3586 | – – – – – – | – – – – – – |               |               |
| 6 Month         | 0.9 ± 0.2 (101) | 0.9 ± 0.2 (92) | 0.3175 | <.0001* | – – – – – – | – – – – – – |               |               |
| 1 Year          | 0.9 ± 0.2 (86) | 0.9 ± 0.2 (90) | 0.2969 | <.0001* | 0.0872 | – – – – – – | – – – – – – |               |
| 2 Year          | 0.9 ± 0.2 (72) | 0.9 ± 0.2 (72) | 0.2811 | <.0001* | <.0001* | <.0001* | – – – – – – |               |
| 3 Year          | 0.9 ± 0.2 (71) | 0.9 ± 0.2 (72) | 0.1534 | <.0001* | 1.0000 | 1.0000 | – – – – – – |               |
| 5 Year          | 1.0 ± 0.1 (39) | 0.9 ± 0.1 (34) | 0.1259 | <.0001* | <.0001* | 0.2561 | 1.0000 | – – – – – – |               |
| HHS             |          |          |            |          |          |            |          |
| Preop           | 50.3 ± 12.2 (113) | 48.7 ± 13.5 (109) | 0.2623 | – – – – – – | – – – – – – |               |               |
| 6 Month         | 93.0 ± 9.8 (100) | 94.6 ± 7.7 (94) | 0.2602 | <.0001* | – – – – – – | – – – – – – |               |               |
| 1 Year          | 96.1 ± 7.7 (85) | 96.6 ± 5.5 (92) | 0.8948 | <.0001* | <.0001* | <.0001* | – – – – – – |               |
| 2 Year          | 96.5 ± 7.8 (72) | 96.1 ± 6.5 (72) | 0.1446 | <.0001* | <.0001* | 0.2509 | – – – – – – |               |
| 3 Year          | 96.2 ± 8.3 (71) | 97.6 ± 5.7 (71) | 0.29 | <.0001* | 0.0003* | 1.0000 | 1.0000 | – – – – – – |               |
| 5 Year          | 98.4 ± 2.9 (39) | 96.1 ± 5.9 (34) | 0.0733 | <.0001* | <.0001* | 0.2266 | 0.3864 | 1.0000 | – – – – – – |
| Oxford          |          |          |            |          |          |            |          |
| Preop           | 22.2 ± 7.4 (113) | 21.9 ± 7.9 (109) | 0.8968 | – – – – – – | – – – – – – |               |               |
| 6 Month         | 43.8 ± 5.4 (101) | 42.9 ± 5.5 (94) | 0.1147 | <.0001* | – – – – – – | – – – – – – |               |               |
| 1 Year          | 45.0 ± 5.4 (86) | 44.6 ± 4.3 (92) | 0.0776 | <.0001* | 0.0180* | – – – – – – | – – – – – – |               |
| 2 Year          | 45.5 ± 4.6 (73) | 45.2 ± 3.9 (72) | 0.1347 | <.0001* | 0.0001* | 1.0000 | – – – – – – |               |
| 3 Year          | 45.7 ± 4.8 (71) | 45.9 ± 3.2 (71) | 0.1796 | <.0001* | 0.0024* | 1.0000 | 1.0000 | – – – – – – |               |
| 5 Year          | 46.8 ± 1.9 (42) | 46.0 ± 3.3 (34) | 0.2548 | <.0001* | <.0001* | 0.4758 | 1.0000 | 1.0000 | – – – – – – |
| Aluminum (µg/L) |          |          |            |          |          |            |          |
| Preop           | 12.3 ± 1.9 (21) | 11.6 ± 1.7 (10) | 0.183 | – – – – – – | – – – – – – | – – – – – – | – – – – – – |
| 6 Month         | 12.3 ± 1.8 (16) | 11.9 ± 1.8 (9) | 0.5903 | 1.0000 | – – – – – – | – – – – – – | – – – – – – | – – – – – – |
| 1 Year          | 13.9 ± 3.2 (13) | 14.5 ± 4.2 (11) | 0.7495 | 1.0000 | 1.0000 | – – – – – – | – – – – – – | – – – – – – |
| 2 Year          | 13.3 ± 2.0 (12) | 14.4 ± 5.3 (9) | 0.2267 | 1.0000 | 1.0000 | 1.0000 | – – – – – – | – – – – – – |
| 5 Year          | 14.7 ± 3.1 (4) | 13.4 ± 1.5 (3) | 0.2888 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | – – – – – – | – – – – – – |
| Titanium (µg/L) |          |          |            |          |          |            |          |
| Preop           | 2.1 ± 0.6 (4) | 1.2 ± 0.9 (5) | 0.6242 | – – – – – – | – – – – – – | – – – – – – | – – – – – – | – – – – – – |
| 6 Month         | 2.1 ± 1.3 (29) | 2.4 ± 2.3 (14) | 0.1859 | 1.0000 | – – – – – – | – – – – – – | – – – – – – | – – – – – – |
| 1 Year          | 2.0 ± 1.1 (20) | 2.4 ± 2.3 (15) | 0.137 | 1.0000 | 1.0000 | – – – – – – | – – – – – – | – – – – – – |
| 2 Year          | 2.2 ± 0.8 (15) | 2.4 ± 3.4 (12) | 0.0667 | 1.0000 | 1.0000 | 1.0000 | – – – – – – | – – – – – – |
| 5 Year          | 1.3 ± 1.3 (3) | 1.2 ± 0.2 (2) | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | – – – – – – |

R. D'Ambrosi et al.: SICOT-J 2022, 8, 9.
Table A.7. Subgroup analysis by primary diagnosis.

| Follow up visit | Mean value and comparison within time period | Comparison by time within subgroups (Bonferroni adjusted p-value) |
|-----------------|--------------------------------------------|---------------------------------------------------------------|
|                 | UCLA                                       |                                                               |
|                 | Mean ± SD (n)                              | p-value                                                       |
|                 | Preop                                      | 6 Month 1 Year 2 Year 3 Year                                  |
|                 | Unadjusted mean ± SD (n)                   |                                                               |
|                 | Osteoarthritis                             | Other diagnosis                                              |
|                 | Preop                                      | 6 Month 1 Year 2 Year 3 Year                                  |
|                 | Unadjusted mean ± SD (n)                   |                                                               |
|                 | 4.0 ± 1.6 (179)                            | 3.4 ± 1.3 (43)                                                |
|                 | 5.5 ± 1.4 (155)                            | 5.6 ± 1.5 (40)                                                |
|                 | 5.8 ± 1.6 (140)                            | 6.2 ± 1.6 (38)                                                |
|                 | 5.9 ± 1.7 (115)                            | 6.6 ± 1.2 (30)                                                |
|                 | 6.2 ± 1.6 (112)                            | 6.3 ± 1.5 (31)                                                |
|                 | 6.5 ± 1.5 (24)                             | 6.3 ± 1.4 (52)                                                |
|                 | 0.5 ± 0.3 (179)                            | 0.3 ± 0.3 (43)                                                |
|                 | 0.9 ± 0.1 (154)                            | 0.8 ± 0.2 (39)                                                |
|                 | 0.9 ± 0.1 (138)                            | 0.9 ± 0.2 (38)                                                |
|                 | 0.9 ± 0.2 (114)                            | 0.9 ± 0.1 (30)                                                |
|                 | 0.9 ± 0.2 (112)                            | 0.9 ± 0.2 (31)                                                |
|                 | 1.0 ± 0.1 (50)                             | 0.9 ± 0.1 (23)                                                |
|                 | 51.0 ± 12.4 (179)                          | 43.5 ± 13.1 (43)                                              |
|                 | 94.5 ± 8.3 (155)                           | 90.9 ± 10.6 (39)                                             |
|                 | 96.4 ± 6.8 (139)                           | 96.0 ± 6.3 (38)                                              |
|                 | 96.2 ± 7.7 (114)                           | 96.9 ± 4.6 (30)                                              |
|                 | 96.8 ± 7.4 (111)                           | 97.3 ± 6.2 (31)                                              |
|                 | 97.2 ± 4.8 (50)                            | 97.5 ± 4.517 (23)                                            |
|                 | 22.9 ± 7.4 (179)                           | 18.7 ± 7.6 (43)                                              |
|                 | 43.8 ± 5.1 (155)                           | 41.6 ± 6.3 (40)                                              |
|                 | 44.8 ± 4.8 (140)                           | 45.0 ± 4.8 (38)                                              |
|                 | 45.1 ± 4.6 (115)                           | 46.3 ± 2.6 (30)                                              |
|                 | 45.5 ± 4.3 (111)                           | 47.0 ± 2.6 (31)                                              |
|                 | 46.2 ± 2.5 (52)                            | 46.8 ± 2.9 (24)                                              |
|                 | 12.0 ± 1.8 (29)                            | 13.8 ± 0.6 (2)                                               |
|                 | 12.1 ± 1.8 (22)                            | 12.9 ± 1.8 (3)                                               |
|                 | 14.5 ± 3.8 (21)                            | 12.3 ± 2.3 (3)                                               |
|                 | 13.4 ± 3.8 (18)                            | 16.0 ± 2.1 (3)                                               |
|                 | 14.0 ± 2.3 (5)                             | 14.5 ± 4.0 (2)                                               |
|                 | 2.1 ± 0.7 (8)                              | 2.8 ± 0.1 (1)                                                |
|                 | 2.4 ± 1.7 (37)                             | 2.2 ± 2.1 (6)                                                |
|                 | 2.5 ± 1.8 (29)                             | 2.2 ± 1.9 (6)                                                |
|                 | 2.9 ± 2.5 (24)                             | 3.1 ± 1.9 (3)                                                |
|                 | 1.3 ± 0.3 (4)                              | 1.3 ± 0.1 (1)                                                |

Note: The values represent the unadjusted mean ± standard deviation (SD) followed by the Bonferroni adjusted p-value for comparison within subgroups.
Table A.8. Subgroup analysis by tobacco consumption.

| Follow up visit | Mean value and comparison within time period | Comparison by time within subgroups (Bonferroni adjusted \( p \)-value) |
|-----------------|------------------------------------------|-------------------------------------------------|
|                 | Smokers | Non smokers | Smokers | Non smokers | Smokers | Non smokers |
|                 | Unadjusted mean ± SD \( n \) | Unadjusted mean ± SD \( n \) | Preop | 6 Month | 1 Year | 2 Year | 3 Year | Preop | 6 Month | 1 Year | 2 Year | 3 Year |
| UCLA            |         |             |         |         |         |         |         |         |         |         |         |         |
| Preop           | 3.9 ± 1.4 (26) | 3.8 ± 1.6 (196) | 0.7261 | – | – | – | – | – | – | – | – | – |
| 6 Month         | 5.0 ± 1.2 (23) | 5.6 ± 1.4 (172) | 0.0699 | 0.0042* | 1.0000 | – | – | – | – | – | – | – |
| 1 Year          | 6.2 ± 1.8 (17) | 5.9 ± 1.6 (161) | 0.4296 | 0.0081* | 1.0000 | – | – | – | – | – | – | – |
| 2 Year          | 6.2 ± 1.7 (16) | 6.1 ± 1.6 (129) | 0.8755 | 0.0110* | 0.8057 | 1.0000 | – | – | – | – | – | – |
| 3 Year          | 6.0 ± 1.5 (16) | 6.2 ± 1.6 (127) | 0.5333 | 0.0037* | 1.0000 | 1.0000 | 1.0000 | – | – | – | – | – |
| 5 Year          | 6.4 ± 0.9 (5) | 6.5 ± 1.5 (71) | 0.8722 | 0.0042* | 0.2710 | 1.0000 | 1.0000 | 1.0000 | – | – | – | – |
| EQ5D            |         |             |         |         |         |         |         |         |         |         |         |         |
| Preop           | 0.4 ± 0.3 (26) | 0.5 ± 0.3 (196) | 0.2153 | – | – | – | – | – | – | – | – | – |
| 6 Month         | 0.9 ± 0.1 (23) | 0.9 ± 0.2 (170) | 0.4689 | <0.001* | – | – | – | – | – | – | – | – |
| 1 Year          | 1.0 ± 0.1 (17) | 0.9 ± 0.2 (159) | 0.1436 | 0.0002* | 0.2344 | – | – | – | – | – | – | – |
| 2 Year          | 0.9 ± 0.3 (16) | 0.9 ± 0.1 (128) | 0.7519 | 0.0023* | 1.0000 | 1.0000 | 1.0000 | – | – | – | – | – |
| 3 Year          | 0.9 ± 0.2 (16) | 0.9 ± 0.2 (127) | 0.314 | 0.005* | 1.0000 | 1.0000 | 1.0000 | – | – | – | – | – |
| 5 Year          | 1.0 ± 0.0 (5) | 0.9 ± 0.1 (68) | 0.2161 | 0.9375 | 1.0000 | 1.0000 | 1.0000 | – | – | – | – | – |
| HHS             |         |             |         |         |         |         |         |         |         |         |         |         |
| Preop           | 49.2 ± 11.8 (26) | 49.5 ± 13.0 (196) | 0.8863 | – | – | – | – | – | – | – | – | – |
| 6 Month         | 97.4 ± 4.3 (23) | 93.3 ± 9.2 (171) | 0.0289* | <0.001* | – | – | – | – | – | – | – | – |
| 1 Year          | 98.5 ± 3.1 (17) | 96.1 ± 6.9 (160) | 0.1225 | 0.0002* | 1.0000 | – | – | – | – | – | – | – |
| 2 Year          | 98.3 ± 3.6 (16) | 96.1 ± 7.4 (128) | 0.207 | 0.005* | 1.0000 | 1.0000 | 1.0000 | – | – | – | – | – |
| 3 Year          | 98.2 ± 2.6 (16) | 96.8 ± 7.5 (126) | 0.5922 | 0.005* | 1.0000 | 1.0000 | 1.0000 | – | – | – | – | – |
| 5 Year          | 99.0 ± 1.4 (5) | 97.2 ± 4.8 (68) | 0.6121 | 0.9375 | 1.0000 | 1.0000 | 1.0000 | – | – | – | – | – |
| HHS             |         |             |         |         |         |         |         |         |         |         |         |         |
| Preop           | 20.7 ± 6.2 (26) | 22.2 ± 7.8 (196) | 0.2549 | – | – | – | – | – | – | – | – | – |
| 6 Month         | 44.7 ± 4.1 (23) | 43.2 ± 5.6 (172) | 0.2523 | <0.001* | – | – | – | – | – | – | – | – |
| 1 Year          | 47.0 ± 1.7 (17) | 44.6 ± 5.0 (161) | 0.0420* | 0.0002* | 0.0073* | – | – | – | – | – | – | – |
| 2 Year          | 45.9 ± 3.7 (16) | 45.3 ± 4.3 (129) | 0.4761 | 0.0005* | 1.0000 | 1.0000 | 1.0000 | – | – | – | – | – |
| 3 Year          | 46.9 ± 1.6 (16) | 45.7 ± 4.2 (126) | 0.5381 | 0.005* | 0.0152 | 1.0000 | 1.0000 | – | – | – | – | – |
| 5 Year          | 47.2 ± 1.3 (5) | 46.4 ± 2.7 (71) | 0.5873 | 0.9375 | 1.0000 | 1.0000 | 1.0000 | – | – | – | – | – |
| Aluminum (\( \mu g/L \)) |         |             |         |         |         |         |         |         |         |         |         |         |
| Preop           | 12.7 ± 1.8 (3) | 12.0 ± 1.9 (28) | 0.3002 | – | – | – | – | – | – | – | – | – |
| 6 Month         | 11.0 ± 1.8 (5) | 12.5 ± 1.8 (72) | 0.6434 | 1.0000 | – | – | – | – | – | – | – | – |
| 1 Year          | 14.1 ± 3.8 (5) | 14.2 ± 4.0 (19) | 0.2143 | 1.0000 | 0.75 | – | – | – | – | – | – | – |
| 2 Year          | 12.3 ± 3.8 (4) | 14.1 ± 4.0 (17) | 0.5015 | 1.0000 | 1.0000 | 1.0000 | – | 1.0000 | 1.0000 | 1.0000 | – | – |
| 5 Year          | (0) | 14.1 ± 2.5 (7) | – | – | – | – | – | 1.0000 | 1.0000 | 1.0000 | – | – |
| Titanium (\( \mu g/L \)) |         |             |         |         |         |         |         |         |         |         |         |         |
| Preop           | 1.1 ± 0.1 (1) | 2.3 ± 0.6 (8) | 0.1213 | – | – | – | – | – | – | – | – | – |
| 6 Month         | 1.9 ± 1.0 (10) | 2.5 ± 1.9 (33) | 0.3071 | 1.0000 | – | – | – | – | – | – | – | – |
| 1 Year          | 4.5 ± 2.3 (5) | 2.2 ± 1.5 (30) | 0.0376* | 0.1000 | 0.6250 | – | – | – | – | – | – | – |
| 2 Year          | 3.3 ± 0.6 (5) | 2.8 ± 2.7 (22) | 0.0243* | 1.0000 | 1.0000 | 1.0000 | – | – | – | – | – | – |
| 5 Year          | (0) | 1.3 ± 0.3 (5) | – | – | – | – | – | 1.0000 | 1.0000 | 1.0000 | – | – |
### Table A.9. Subgroup analysis by alcohol consumption.

| Follow up visit | Mean value and comparison within time period | Comparison by time within subgroups (Bonferroni adjusted p-value) |
|-----------------|---------------------------------------------|---------------------------------------------------------------|
|                 | Alcohol consumers | Non alcohol consumers | p-value | Alcohol consumers | Non alcohol consumers |
|                 | Unadjusted mean ± SD (n) | Unadjusted mean ± SD (n) | | Preop | 6 Month | 1 Year | 2 Year | 3 Year | Preop | 6 Month | 1 Year | 2 Year | 3 Year |
| UCLA            |                             |                             |          |                   |                   |
| Preop           | 4.5 ± 1.7 (73)             | 3.5 ± 1.5 (149)             | <.0001*  | –                  | –                  |
| 6 Month         | 5.6 ± 1.4 (65)             | 5.5 ± 1.4 (130)             | 0.4434   | –                  | –                  |
| 1 Year          | 6.2 ± 1.6 (64)             | 5.7 ± 1.6 (114)             | 0.0064*  | –                  | –                  |
| 2 Year          | 6.5 ± 1.6 (54)             | 5.8 ± 1.6 (91)              | 0.0125*  | –                  | –                  |
| 3 Year          | 6.4 ± 1.5 (54)             | 6.1 ± 1.7 (89)              | 0.1955   | –                  | –                  |
| 5 Year          | 7.0 ± 1.3 (28)             | 6.1 ± 1.4 (48)              | 0.0195*  | –                  | –                  |
| EQ5D            |                             |                             |          |                   |                   |
| Preop           | 0.4 ± 0.3 (73)             | 0.5 ± 0.3 (149)             | 0.634    | –                  | –                  |
| 6 Month         | 0.9 ± 0.2 (64)             | 0.9 ± 0.2 (129)             | 0.4121   | –                  | –                  |
| 1 Year          | 0.9 ± 0.1 (63)             | 0.9 ± 0.2 (113)             | 0.9971   | –                  | –                  |
| 2 Year          | 0.9 ± 0.2 (54)             | 0.9 ± 0.1 (90)              | 0.1211   | –                  | –                  |
| 3 Year          | 0.9 ± 0.2 (54)             | 0.9 ± 0.2 (89)              | 0.708    | –                  | –                  |
| 5 Year          | 1.0 ± 0.1 (27)             | 0.9 ± 0.1 (46)              | 0.2379   | –                  | –                  |
| HHS             |                             |                             |          |                   |                   |
| Preop           | 51.9 ± 13.7 (73)           | 48.3 ± 12.3 (149)           | 0.0638   | –                  | –                  |
| 6 Month         | 92.6 ± 7.9 (64)            | 94.4 ± 9.3 (130)            | 0.0091*  | –                  | –                  |
| 1 Year          | 96.0 ± 7.4 (64)            | 96.5 ± 6.2 (113)            | 0.6825   | –                  | –                  |
| 2 Year          | 97.2 ± 6.2 (54)            | 95.8 ± 7.6 (90)             | 0.0749   | –                  | –                  |
| 3 Year          | 97.2 ± 6.9 (53)            | 96.7 ± 7.3 (89)             | 0.832    | –                  | –                  |
| 5 Year          | 97.9 ± 3.5 (28)            | 97.0 ± 5.3 (45)             | 0.7873   | –                  | –                  |
| Oxford          |                             |                             |          |                   |                   |
| Preop           | 23.3 ± 7.3 (73)            | 21.4 ± 7.7 (149)            | 0.1289   | –                  | –                  |
| 6 Month         | 42.4 ± 5.1 (64)            | 43.8 ± 5.6 (131)            | 0.0017*  | –                  | –                  |
| 1 Year          | 44.8 ± 4.9 (64)            | 44.8 ± 4.8 (114)            | 0.7546   | –                  | –                  |
| 2 Year          | 45.6 ± 3.3 (54)            | 45.2 ± 4.7 (91)             | 0.9398   | –                  | –                  |
| 3 Year          | 45.9 ± 3.8 (54)            | 45.7 ± 4.2 (88)             | 0.3502   | –                  | –                  |
| 5 Year          | 46.7 ± 2.4 (28)            | 46.3 ± 2.8 (48)             | 0.2696   | –                  | –                  |
| Aluminum (μg/L)|                             |                             |          |                   |                   |
| Preop           | 11.0 ± 0.6 (2)             | 12.2 ± 1.9 (29)             | 0.2957   | –                  | –                  |
| 6 Month         | (0)                        | 12.2 ± 1.8 (25)             | –        | –                  | –                  |
| 1 Year          | (0)                        | 14.2 ± 3.6 (24)             | –        | –                  | –                  |
| 2 Year          | 12.7 ± 1.4 (2)             | 13.9 ± 3.8 (19)             | 0.9522   | 1.0000             | –                  |
| 5 Year          | (0)                        | 14.1 ± 2.5 (7)              | –        | 1.0000             | –                  |
| Titanium (μg/L)|                             |                             |          |                   |                   |
| Preop           | (0)                        | 2.1 ± 0.7 (9)               | –        | –                  | –                  |
| 6 Month         | (0)                        | 2.4 ± 1.7 (43)              | –        | –                  | –                  |
| 1 Year          | 6.0 ± 0.1 (1)              | 2.4 ± 1.7 (34)              | 0.1646   | –                  | –                  |
| 2 Year          | 3.1 ± 0.8 (2)              | 2.9 ± 2.5 (25)              | 0.3075   | 1.0000             | –                  |
| 5 Year          | (0)                        | 1.3 ± 0.3 (5)               | –        | 1.0000             | –                  |

14 R. D Ambrosi et al.: SICOT-J 2022, 8, 9
| Follow up visit | Mean value and comparison within time period | Comparison by time within subgroups (Bonferroni adjusted p-value) |
|----------------|---------------------------------------------|---------------------------------------------------------------|
|                | <10                                         | ≥10                                           |
|                | UCLA                                        |                                               |
|                | Unadjusted mean ± SD (n)                    | Unadjusted mean ± SD (n)                              |
|                | Preop 3.5 ± 1.3 (93)                        | 4.1 ± 1.7 (129)                                    |
|                | 5.6 ± 1.4 (84)                              | 5.5 ± 1.4 (111)                                   |
|                | 6.2 ± 1.5 (72)                              | 5.7 ± 1.6 (106)                                   |
|                | 6.2 ± 1.5 (64)                              | 6.0 ± 1.7 (81)                                    |
|                | 6.3 ± 1.4 (62)                              | 6.1 ± 1.7 (81)                                    |
|                | 6.5 ± 1.4 (44)                              | 6.3 ± 1.5 (32)                                    |
|                | EQ5D                                        |                                               |
|                | Preop 0.4 ± 0.3 (93)                        | 0.5 ± 0.3 (129)                                    |
|                | 0.9 ± 0.2 (81)                              | 0.9 ± 0.2 (112)                                   |
|                | 0.9 ± 0.2 (71)                              | 0.9 ± 0.2 (105)                                   |
|                | 0.9 ± 0.2 (64)                              | 0.9 ± 0.2 (80)                                    |
|                | 0.9 ± 0.1 (62)                              | 0.9 ± 0.2 (81)                                    |
|                | 1.0 ± 0.1 (41)                              | 0.9 ± 0.1 (32)                                    |
|                | HHS                                         |                                               |
|                | Preop 47.9 ± 13.1 (93)                      | 50.7 ± 12.6 (129)                                  |
|                | 93.0 ± 9.2 (82)                             | 94.3 ± 8.6 (112)                                  |
|                | 95.7 ± 6.3 (71)                             | 96.8 ± 6.9 (106)                                  |
|                | 96.3 ± 5.8 (63)                             | 96.4 ± 8.1 (81)                                   |
|                | 98.5 ± 2.7 (61)                             | 95.7 ± 8.9 (81)                                   |
|                | 97.7 ± 3.8 (42)                             | 96.7 ± 5.7 (31)                                   |
|                | Oxford                                      |                                               |
|                | Preop 21.4 ± 7.6 (93)                       | 22.6 ± 7.7 (129)                                  |
|                | 42.6 ± 6.0 (83)                             | 44.0 ± 5.0 (112)                                  |
|                | 44.9 ± 5.0 (72)                             | 44.7 ± 4.7 (106)                                  |
|                | 45.5 ± 3.3 (64)                             | 45.2 ± 4.9 (81)                                   |
|                | 46.6 ± 2.4 (61)                             | 45.2 ± 4.8 (81)                                   |
|                | 46.8 ± 2.0 (44)                             | 45.9 ± 3.3 (32)                                   |
|                | Aluminum (μg/L)                             |                                               |
|                | Preop 12.1 ± 2.5 (10)                       | 12.1 ± 1.5 (21)                                   |
|                | 11.6 ± 1.8 (9)                              | 12.5 ± 1.7 (16)                                   |
|                | 16.6 ± 5.3 (6)                              | 13.4 ± 2.6 (18)                                   |
|                | 13.4 ± 3.0 (6)                              | 13.9 ± 4.0 (15)                                   |
|                | 14.4 ± 0 (1)                               | 14.1 ± 2.7 (6)                                    |
|                | Titanium (μg/L)                             |                                               |
|                | Preop 1.7 ± 1.7 (4)                         | 2.5 ± 0.6 (5)                                     |
|                | 2.7 ± 2.7 (16)                              | 2.2 ± 1.4 (27)                                    |
|                | 2.8 ± 2.8 (10)                              | 2.4 ± 1.6 (25)                                    |
|                | 2.9 ± 2.9 (8)                               | 2.9 ± 2.9 (19)                                    |
|                | 5 Year                                      | 1.3 ± 0.3 (5)                                     |
Table A.11. Group analysis by previous surgery.

| Follow up visit | Mean value and comparison within time period | Comparison by time within subgroups (Bonferroni adjusted p-value) |  |
|----------------|---------------------------------------------|---------------------------------------------------------------|---|
|                | Previous surgery | No previous surgery | p-value | Preop | 6 Month | 1 Year | 2 Year | 3 Year | Preop | 6 Month | 1 Year | 2 Year | 3 Year |  |
| UCLA           | Unadjusted mean ± SD (n) | Unadjusted mean ± SD (n) | p-value | | | | | | | | | | | | |
| Preop          | 4.1 ± 1.4 (55) | 3.8 ± 1.7 (167) | 0.0400* | | | | | | | | | | | | |
| 6 Month        | 5.6 ± 1.2 (49) | 5.5 ± 1.5 (146) | 0.5119 | | | | | | | | | | | | |
| 1 Year         | 6.0 ± 1.6 (42) | 5.9 ± 1.6 (136) | 0.6423 | | | | | | | | | | | | |
| 2 Year         | 6.3 ± 1.8 (34) | 6.0 ± 1.6 (111) | 0.2617 | | | | | | | | | | | | |
| 3 Year         | 6.2 ± 1.7 (31) | 6.2 ± 1.6 (112) | 0.8897 | | | | | | | | | | | | |
| 5 Year         | 6.6 ± 1.3 (18) | 6.4 ± 1.5 (58) | 0.8182 | | | | | | | | | | | | |
| EQSD           | 0.4 ± 0.3 (55) | 0.5 ± 0.3 (167) | 0.7091 | | | | | | | | | | | | |
| Preop          | 49.4 ± 11.7 (55) | 49.5 ± 13.3 (167) | 0.5833 | | | | | | | | | | | | |
| 6 Month        | 93.2 ± 9.1 (49) | 94.0 ± 8.8 (145) | 0.44 | | | | | | | | | | | | |
| 1 Year         | 95.9 ± 7.5 (42) | 96.5 ± 6.4 (135) | 0.7247 | | | | | | | | | | | | |
| 2 Year         | 96.3 ± 6.7 (34) | 96.4 ± 7.3 (110) | 0.2937 | | | | | | | | | | | | |
| 3 Year         | 95.1 ± 10.4 (31) | 97.4 ± 5.8 (111) | 0.4157 | | | | | | | | | | | | |
| 5 Year         | 97.6 ± 3.7 (16) | 97.2 ± 4.9 (57) | 0.9699 | | | | | | | | | | | | |
| HHS            | | | | | | | | | | | | | | | |
| Preop          | 23.0 ± 7.9 (55) | 21.8 ± 7.5 (167) | 0.3217 | | | | | | | | | | | | |
| 6 Month        | 43.8 ± 5.3 (49) | 43.2 ± 5.3 (146) | 0.3921 | | | | | | | | | | | | |
| 1 Year         | 43.7 ± 4.2 (42) | 45.1 ± 4.2 (136) | 0.1258 | | | | | | | | | | | | |
| 2 Year         | 45.4 ± 4.3 (34) | 45.3 ± 4.3 (111) | 0.9098 | | | | | | | | | | | | |
| 3 Year         | 44.9 ± 3.2 (31) | 46.1 ± 3.2 (111) | 0.8579 | | | | | | | | | | | | |
| 5 Year         | 47.0 ± 2.9 (18) | 46.2 ± 2.9 (58) | 0.3734 | | | | | | | | | | | | |
| Oxford         | | | | | | | | | | | | | | | |
| Preop          | 13.6 ± 3.1 (5) | 11.8 ± 1.4 (26) | 0.1469 | | | | | | | | | | | | |
| 6 Month        | 12.5 ± 2.0 (7) | 12.1 ± 1.7 (18) | 0.6065 | 1.0000 | | | | | | | | | 1.0000 | | |
| 1 Year         | 18.8 ± 6.8 (3) | 13.5 ± 2.7 (21) | 0.0881 | 1.0000 | | | | | | | | | 1.0000 | | |
| 2 Year         | 16.0 ± 6.1 (5) | 12.9 ± 1.8 (15) | 0.7851 | 1.0000 | 1.0000 | | | | | | | | 1.0000 | | |
| 5 Year         | 14.1 ± 0 (1) | 14.1 ± 2.7 (6) | 0.6171 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | | | | | | | 1.0000 | |
| Titanium (μg/L)| | | | | | | | | | | | | | | |
| Preop          | 2.2 ± 0.7 (7) | 2.1 ± 1.1 (2) | 1.0000 | | | | | | | | | | | | |
| 6 Month        | 3.3 ± 2.0 (12) | 2.0 ± 1.5 (31) | 0.0006 | 1.0000 | | | | | | | | | 1.0000 | | |
| 1 Year         | 3.7 ± 2.4 (7) | 2.2 ± 1.5 (28) | 0.0131* | 1.0000 | 1.0000 | | | | | | | | 1.0000 | | |
| 2 Year         | 3.9 ± 4.3 (8) | 2.5 ± 1.0 (19) | 0.632 | 1.0000 | 1.0000 | 1.0000 | | | | | | | 1.0000 | | |
| 5 Year         | 1.1 ± 0 (1) | 1.4 ± 0.3 (4) | 0.4795 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | | | | | | | 1.0000 | |
| Variables                      | Rho       | p-value  | N  |
|-------------------------------|-----------|----------|----|
| **BMI**                       |           |          |    |
| UCLA (2 Year)                 | -0.23     | 0.0056*  | 145|
| TITANIUM (6 Month)            | 0.38      | 0.0132*  | 43 |
| TITANIUM (1 Year)             | 0.39      | 0.0210*  | 35 |
| **Age**                       |           |          |    |
| UCLA (6 Month)                | -0.20     | 0.0058*  | 195|
| UCLA (1 Year)                 | -0.45     | <.0001*  | 178|
| UCLA (2 Year)                 | -0.46     | <.0001*  | 145|
| UCLA (3 Year)                 | -0.45     | <.0001*  | 143|
| UCLA (5 Year)                 | -0.39     | 0.0066*  | 76 |
| E Frage 3 (Year)              | -0.24     | 0.0414*  | 73 |
| HHS (2 Year)                  | -0.17     | 0.0476*  | 144|
| HHS (3 Year)                  | -0.21     | 0.0095*  | 142|
| HHS (5 Year)                  | -0.31     | 0.0077*  | 73 |
| OXFORD (1 Year)               | -0.21     | 0.0050*  | 178|
| OXFORD (2 Year)               | -0.22     | 0.0087*  | 145|
| OXFORD (5 Year)               | -0.26     | 0.0249*  | 76 |
| **Gender (female)**           |           |          |    |
| UCLA (Preop)                  | -0.21685  | 0.0011*  | 222|
| UCLA (6 Month)                | -0.21     | 0.0031*  | 195|
| UCLA (5 Year)                 | -0.28     | 0.0132*  | 76 |
| EqFrag 6 (Preop)              | -0.21     | 0.0014*  | 222|
| EqFrag 6 (6 Month)            | -0.18     | 0.0101*  | 193|
| HHS (Preop)                   | -0.22     | 0.0090*  | 222|
| HHS (6 Month)                 | -0.25     | 0.0005*  | 194|
| HHS (1 Year)                  | -0.25     | 0.0009*  | 177|
| HHS (2 Year)                  | -0.20     | 0.0149*  | 144|
| OXFORD (Preop)                | -0.25     | 0.0001*  | 222|
| OXFORD (6 Month)              | -0.25     | 0.0005*  | 195|
| OXFORD (1 Year)               | -0.15     | 0.0416*  | 178|
| OXFORD (2 Year)               | -0.23     | 0.0056*  | 145|
| **Smoke**                     |           |          |    |
| Surgical time                 | -0.15     | 0.0277*  | 222|
| HHS (6 Month)                 | 0.16      | 0.0285*  | 194|
| OXFORD (Preop)                | 0.15      | 0.0416*  | 178|
| TITANIUM (1 Year)             | 0.37      | 0.0355*  | 35 |
| TITANIUM (2 Year)             | 0.44      | 0.0211*  | 27 |
| **Alcohol consumption**       |           |          |    |
| UCLA (Preop)                  | 0.29      | <.0001*  | 222|
| UCLA (1 Year)                 | 0.20      | 0.0061*  | 178|
| UCLA (2 Year)                 | 0.21      | 0.0120*  | 145|
| UCLA (5 Year)                 | 0.27      | 0.0185*  | 76 |
| HHS (6 Month)                 | -0.19     | 0.0088*  | 194|
| OXFORD (6 Month)              | -0.22     | 0.0016*  | 195|
| **Previous surgery**          |           |          |    |
| UCLA (Preop)                  | 0.14      | 0.0397*  | 222|
| TITANIUM (6 Month)            | 0.53      | 0.0003*  | 43 |
| TITANIUM (1 Year)             | 0.43      | 0.0108*  | 35 |
| **Femoral size**              |           |          |    |
| UCLA (Preop)                  | 0.15      | 0.0242*  | 222|
| EqFrag 6 (Preop)              | 0.14      | 0.0381*  | 222|
| HHS (1 Year)                  | 0.20      | 0.0081*  | 177|
| OXFORD (6 Month)              | 0.22      | 0.0022*  | 195|
| ALUMINUM (6 Month)            | 0.40      | 0.0476*  | 25 |
| TITANIUM (Preop)              | 0.69      | 0.0399*  | 9  |
| TITANIUM (1 Year)             | -0.36     | 0.0353*  | 35 |
| **Neck version: anteverted**  |           |          |    |
| EqFrag 6 (3 Year)             | -0.20     | 0.0163*  | 143|
| HHS (6 Month)                 | -0.16     | 0.0231*  | 194|
| **Neck version: straight**    |           |          |    |
| EqFrag 6 (2 Year)             | -0.17     | 0.0437*  | 144|
| **Anterolateral surgical approach** |      |          |    |
| UCLA (1 Year)                 | -0.22     | 0.0032*  | 178|
| UCLA (2 Year)                 | -0.24     | 0.0034*  | 145|
| UCLA (3 Year)                 | -0.25     | 0.0030*  | 143|
| EqFrag 6 (1 Year)             | -0.15     | 0.0483*  | 176|
| HHS (Preop)                   | -0.22     | 0.0012*  | 222|
| TITANIUM (Preop)              | 0.87      | 0.0025*  | 9  |
| TITANIUM (2 Year)             | -0.39     | 0.0445*  | 27 |

(Continued on next page)
Variables | Rho | p-value | N  
--- | --- | --- | ---  
**Direct lateral surgical approach**  
Surgical time | 0.53 | <.0001* | 222  
EQ5D (Preop) | −0.13 | 0.0494* | 222  
HHS (6 Month) | −0.22 | 0.0026* | 194  
HHS (1 Year) | −0.18 | 0.0169* | 177  
HHS (2 Year) | −0.23 | 0.0054* | 144  
HHS (3 Year) | −0.28 | 0.0008* | 142  
HHS (5 Year) | −0.29 | 0.0119* | 73  
OXFORD (6 Month) | −0.18 | 0.0114* | 195  
**Posterolateral surgical approach**  
Surgical time | −0.31 | <.0001* | 222  
UCLA (1 Year) | 0.19 | 0.0104* | 178  
UCLA (2 Year) | 0.28 | 0.0006* | 145  
UCLA (3 Year) | 0.28 | 0.0007* | 143  
UCLA (5 Year) | 0.30 | 0.0087* | 76  
HHS (Preop) | 0.16 | 0.0171* | 222  
HHS (5 Year) | 0.25 | 0.0330* | 73  
OXFORD (1 Year) | 0.16 | 0.0312* | 178  
OXFORD (3 Year) | 0.17 | 0.0445* | 142  
TITANIUM (Preop) | −0.87 | 0.0025* | 9  
TITANIUM (2 Year) | 0.39 | 0.0445* | 27